Tirzepatide

FDA ApprovedStrong Evidence
Written by dr-sarah-chen|Reviewed by Healthier Rx Editorial Board|Updated 2026-04-01|4 min read
Quick Facts
TypeGLP-1 / Weight Loss
FDA StatusFDA Approved
Evidence LevelStrong Evidence
Typical Dose2.5-15mg/week
FrequencyOnce weekly
Cycle LengthOngoing
Key GoalsWeight Loss, Metabolic Health, Insulin Resistance

How It Works

Tirzepatide represents the next generation of metabolic therapy. While semaglutide targets a single receptor (GLP-1), tirzepatide targets two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).

It is engineered with a fatty acid side chain that binds to albumin in the blood, giving it a half-life of roughly five days for once-weekly dosing.

The dual mechanism creates synergistic effects: GLP-1 reduces appetite and slows gastric emptying, while GIP enhances the GLP-1 effect on appetite suppression while also improving fat metabolism and insulin sensitivity. GIP specifically targets white adipose tissue, promoting fat breakdown.

Benefits

  • Average 20.9% body weight loss in SURMOUNT-1 (15mg dose, 72 weeks)
  • Over 50% of patients lost more than 20% of body weight
  • Significant improvements in insulin sensitivity and HbA1c
  • Reduction in triglycerides and systemic inflammation
  • Emerging data showing efficacy against fatty liver disease (MASH)
  • Often better tolerated than semaglutide due to GIP's anti-emetic properties

Side Effects

  • Nausea (most common, typically within 24-48 hours of injection, subsides with acclimation)
  • Diarrhea and constipation (altered gastric motility)
  • Fatigue (often related to reduced caloric intake)
  • Injection site reactions (mild redness or itching)
  • Acid reflux (if eating large or high-fat meals)

Dosing Protocol

PhaseDurationWeekly DosePurpose
InitiationWeeks 1-42.5mgAcclimate the body (not a therapeutic dose)
Step 1Weeks 5-85.0mgFirst therapeutic dose
Step 2Weeks 9-127.5mgContinued escalation
Step 3Weeks 13-1610.0mgMaintenance or continued escalation
Step 4Weeks 17-2012.5mgContinued escalation
MaximumWeek 21+15.0mgMaximum therapeutic dose

Many patients achieve significant results at 5.0-10.0mg and do not need to escalate to 15.0mg. Do not rush titration — if you experience severe side effects, stay at the current dose until they subside.

What You Will Need

  • Tirzepatide prescription (via telehealth clinic or endocrinologist)
  • Pre-filled injection pens (brand) or compounded vials with insulin syringes
  • Alcohol swabs
  • Sharps container

Mitigating Side Effects

  • Hydration: Drink significantly more water than usual
  • Small, frequent meals: Large or high-fat meals cause severe discomfort
  • Prioritize protein: 0.8-1g per pound of ideal body weight to preserve muscle
  • Resistance training: Essential to prevent muscle loss during rapid weight loss
  • Do not rush titration: Stay at current dose until side effects subside before escalating

Frequently Asked Questions

References

  1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)New England Journal of Medicine (2022). PMID: 35658024

    Landmark trial showing 20.9% average weight loss at 72 weeks with tirzepatide 15mg in adults with obesity.

  2. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2)New England Journal of Medicine (2021). PMID: 34170647

    Head-to-head trial showing tirzepatide superior to semaglutide for HbA1c reduction and weight loss.

Compare Tirzepatide

Related Goals

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any new treatment or protocol. Read our full medical disclaimer.